About the Authors

Christian Haass

Christian.Haass@dzne.de (CH); dselkoe@bwh.harvard.edu (DS)

Affiliations German Center for Neurodegenerative Diseases (DZNE), Munich, Germany, Metabolic Biochemistry, Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University, Munich, Germany, Munich Cluster for Systems Neurology (SyNergy), Munich, Germany

Dennis Selkoe

Christian.Haass@dzne.de (CH); dselkoe@bwh.harvard.edu (DS)

Affiliation Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, United States of America

Competing Interests

CH and DJS have read the journal’s policy and the authors of this manuscript have the following competing interests. CH collaborates with Denali Therapeutics on microglia related therapeutic strategies. CH is chief advisor of ISAR Bioscience and a member of the advisory board of AviadoBio. CH once joined a review panel of Biogen, which did not include Aducanumab. DJS is a director and consultant to Prothena Biosciences.